Chemo-enzymatic cascades of enzymes with transition metal catalysts can offer efficient synthetic strategies, but their development is challenging due to the incompatibility between proteins and transition metal complexes. Rhodium catalysts can be combined with alcohol dehydrogenases to regenerate nicotinamide cofactors using formate as the hydride donor. However, their use is limited, due to binding of the metals to residues on the enzyme surface, leading to mutual enzyme and catalyst inactivation. In this work, we replaced the zinc from Thermoanaerobacter brockii alcohol dehydrogenase (TbADH) with Rh(III) catalysts possessing nitrogen donor ligands, by covalent conjugation to the active site cysteine, to create artificial metalloenzymes for NADP + reduction. TbADH was used as protein scaffold for both alcohol synthesis and the recycling of the cofactor, by combination of the chemically modified species with the non-modified recombinant enzyme. Stability studies revealed that the incorporation of the catalysts into the TbADH pocket provided a shielding environment for the metal catalyst, resulting in increased stability of both the recycling catalyst and the ADH. The reduction of a representative ketone using this novel alcohol dehydrogenase-artificial formate dehydrogenase cascade yielded better conversions than in the presence of free metal catalyst.
Introduction
Alcohol dehydrogenases (ADHs) are valuable biocatalytic tools for the conversion of ketones into chiral alcohols, providing a sustainable and efficient alternative to chiral catalysts based on transition metals. 1 The main limitation to their practical application is the requirement of nicotinamide adenine dinucleotide cofactors (NADH or NADPH) as electron donors. The complexity of these structures, associated with high cost and reduced stability, precludes their use as stoichiometric reducing agents. Therefore, the continuous in situ regeneration of the cofactor is necessary for economically acceptable transformations with isolated enzymes. Current state of the art for NAD(P)H recycling is the use of a second catalyst to regenerate the cofactor at the expense of another reducing agent.
2 Enzymatic recycling systems have been developed, inspired by the mechanisms of cofactor balance in living cells, but they are not universally applicable and may suffer from incompatibility between the two enzyme systems and complexity of product purication. 3 Both chemical and electrochemical delivery of reducing potential have been investigated, as simpler and more robust alternatives to enzymatic methods. [2] [3] [4] [5] [6] A very promising option are chemical catalysts based on Rh(III), Ir(III) and to a lesser extent Ru(II), which use formate as a reducing agent.
7-12
Although less active than formate dehydrogenase (turnover frequency $250 times lower for NADH formation for the stateof-the-art Rh complex), 3, 13 they are compatible with high temperatures and solvents, and avoid the complexity associated with a second enzyme. Additionally, organometallic complexes have been shown to recycle the simpler and less expensive synthetic NAD(P)H mimics. 14, 15 Sadler and co-workers also reported the formate-driven reduction of NAD + to NADH catalysed by Ru(II) arene complexes in living cells, albeit with reduced activity compared to the complexes in buffer.
16
The main limitation of these synthetic regeneration catalysts is the incompatibility of the metal complexes with coordinating functionalities present in the mixture, such as accessible amine or thiol groups present in enzymes. [17] [18] [19] Restricting the access of the metal species to the nucleophilic residues on the enzyme surface is required to solve this problem. Attempts to protect the catalysts by separately immobilising the enzyme and the metal complex have been shown to increase process stability, and offered opportunities for catalyst recycling. 4, 6 On the other hand, immobilisation of the catalysts resulted in decreased catalytic activity due to diffusion limitations.
20
As an alternative to the immobilisation on solid support, articial metalloenzymes are constructed by encapsulation of metal-based catalysts inside protein scaffolds, thus overcoming mass transfer limitations by keeping the catalytic moiety and the reagents in homogeneous phase. They have been explored as a synergistic method in catalyst design, by coupling the selectivity of enzymes with versatile, human-devised, catalytic functionality, to afford synthetic capabilities greater than the sum of the parts. 21 Articial metalloenzymes have been shown to facilitate a range of synthetic reaction chemistries, from reductions of carbon-carbon and carbon-heteroatom bonds, to oxygen insertion and carbon-carbon bond formation.
21-27
The reduction of NAD(P) + has also been achieved with metal catalysts incorporated into proteins, either by covalent linking to papain, 28 or by supramolecular insertion using the wellestablished biotin-streptavidin system. 29 In this context, Ward and co-workers reported that the protein host also provided a shielding environment for the metal catalyst against inhibitory species present in solution. This concept of "molecular compartmentalisation" has been demonstrated by an increased activity of the protein-bound compared to the free metal complex, when used in situ with various enzymes dependent on NAD(P)H or on NAD(P)H mimics. [30] [31] [32] Whilst a range of cofactordependent biocatalysts have been employed in conjunction with articial metalloenzymes, such as ene reductases, glucose dehydrogenase and 2-hydroxybiphenyl monooxygenase, a cascade reaction with alcohol dehydrogenases remains to be developed. This is most likely due to the ketone reduction activity of the most successful biotinylated Cp*Ir aminosulfonamide complexes reported so far, which would interfere with the ADH activity.
33
In most cases, the design of articial metalloenzymes relies on the availability of a bioconjugation site within the protein scaffold, whilst substrate-binding features are less important in the design. Yet, substrate binding in an enzyme active site can lead to exquisite control over the activation pathway, and thus to promiscuous reactivities, as demonstrated by Hyster and coworkers who used an NADPH-dependent reductase to catalyse radical formation and hydrogen atom transfer.
34
Zincdependent alcohol dehydrogenases are well-suited to build articial enzymes for NAD(P) + reduction: they contain a metalbinding site, a hydrophobic substrate-binding pocket able to accommodate organic ligands, as well as the NAD(P) + cofactorbinding pocket. 35 In this study, we will present the development of hybrid catalysts for NADPH regeneration, by using a zincdependent ADH as host for metal complexes with demonstrated ability to reduce NAD(P) + . In the native ADH reaction, the reduction of NAD(P) + takes place by hydride transfer from an alcohol hydride donor. We reasoned that the replacement of the alcohol by a metal hydride donor will provide the advantage of irreversible hydride transfer from formate to the cofactor. We hypothesise that the use of ADH as the protein scaffold for both alcohol synthesis (natural ADH) and the recycling of the cofactor (chemically modied ADH) will result in an increased robustness of a system where both reactions take place in the same mixture (Fig. 1) . To test this hypothesis, the potential of the protein to prevent metal inactivation will be studied and the new articial metalloenzymes will be compared with nonenzymatic cofactor regeneration catalysts in a synthetic cascade.
Results and discussion

Design and preparation of alcohol dehydrogenase mutants
ADH from the thermophilic species Thermoanaerobacter brockii (TbADH) was selected for bioconjugation to a metal complex catalyst. TbADH is a Zn-dependent bacterial ADH with a homotetrameric structure, in which the catalytic Zn is bound by residues C37, H59 and D150. 36 Its distinguishing feature compared to other medium-chain Zn-dependent ADHs is the absence of a second, structural Zn-binding site. Wild-type TbADH reduces small aliphatic ketones with high enantioselectivity. 37, 38 Of particular interest is its NADP + specicity, as well as its stability at relatively high temperatures (up to 65-86 C) 39 and in the presence of organic solvents. 37, 40 It was reasoned that its robustness would facilitate the introduction of organic ligands within the structure. Covalent anchoring to cysteine was selected as the method for the bioconjugation of metal catalysts. TbADH contains four cysteine residues per monomer ( Fig. 2A) . Two of these have already been covalently labelled with iodoacetic acid: C203 in the NADP + binding pocket and C37 in the Zn-binding site, which could be readily modied in the absence of catalytic Zn. Previous work also showed that C203 could be mutated to serine without loss in enzyme activity.
41
WT TbADH was overexpressed in E. coli and puried by affinity chromatography. The specic activity of this recombinant enzyme was comparable to the native enzyme. 39 The accessibility of the cysteine residues and their reactivity towards 5,5
0 -dithio-bis(2-nitrobenzoic acid) (DTNB) was assessed by Ellman's assay, which indicated the availability of one thiol per enzyme monomer in WT TbADH, presumably C203 according to the structure and previous evidence. 41 The triple mutant C203S-C283A-C295A (hereaer TbADH 3M), obtained by sitedirected mutagenesis, was expressed and puried, showing similar specic activities compared to WT TbADH (Fig. 2B ), thus suggesting that removal of these thiol groups does not signicantly alter the native protein structure. This mutant showed no free thiol content, indicating that C37 was not available for modication in the presence of zinc. Zinc removal was achieved by further mutation of the Zn-coordinating residues to smaller alanine side chains. As expected and conrmed by ICP-MS analysis, double mutant H59A-D150A contained no zinc and its reaction with the Ellman's reagent showed the availability of 1.6 free thiols per monomer for covalent modi-cation. Thus, a working TbADH scaffold containing the ve mutations H59A-D150A-C203S-C283A-C295A (hereaer TbADH 5M) was prepared, devoid of zinc and containing C37 as the only reactive free thiol (Fig. 2B ). It was hypothesized that a metal complex attached to C37 would t within the Zn cavity, and in proximity of the nicotinamide C4 redox site. Bipyridine and phenanthroline ligands containing a bromide functionality (Scheme 1), and their corresponding metal complexes [Cp*Rh(Br-L1)Cl]Cl and [Cp*Rh(Br-L2)Cl]Cl, were prepared according to published procedures (see ESI †). Bromide was chosen as the alkylating functionality, because this allowed the design of the shortest possible anchor between the protein and the metal complex.
Bioconjugation of metal complexes to TbADH
The bioconjugation of brominated ligands to TbADH was assessed by ESI-MS. Labelling of TbADH 5M with Br-L2, containing the bromo acetamide anchor, occurred readily at pH 7, yielding exclusively the mono-labelled protein. The modica-tion with Br-L1, bearing an alkyl bromide functionality, required an increased pH of 8 to achieve more than 50% yield, and also resulted in unselective modication at a second site (see ESI †). Free thiols depletion aer conjugation was assayed by the Ellman's assay and was in good agreement with the residual amount of free 5M observed by ESI-MS.
When the corresponding rhodium complexes were used, the alkylation at pH 7 was more specic than at pH 8 or 9, presumably because of unspecic rhodium binding to deprotonated surface residues at the higher pH. The optimum conditions for the formation of the mono-labelled proteins as the major compounds were obtained by incubating TbADH 5M with 4 equivalents of the metal complex in 100 mM Tris-HCl buffer at pH 7, for 1 h at room temperature. The proteins were subsequently puried by removing the excess labelling agent on PD-10 desalting columns. showed an absorption band at 323 nm, which could not be observed in the non-labelled 5M mutant and was very similar to the absorption of free [Cp*Rh(Br-L1)] 2+ . Similarly, an increase in absorbance compared to 5M was observed for the bioconjugated [Cp*Rh(5M-C37L2)] 2+ above 300 nm, indicating the presence of the rhodium-phenanthroline complex (Fig. 3B) . The characteristic absorbance was very similar for the free and the bioconjugated metal complexes, indicating a similar primary coordination sphere around the rhodium centre.
To assess non-covalent binding of the catalysts outside the active site, the zinc-containing TbADH 3M mutant was treated with the non-brominated Rh catalysts [Cp*Rh(H-L1)Cl]Cl and [Cp*Rh(H-L2)Cl]Cl. Binding of 0.5 equiv. of rhodium to the protein was still observed by ICP-MS, although at a different site from C37, as indicated by the almost completely retained ketone reduction activity of the 3M mutant (data not shown). This suggested that di-labelling of the protein was due to rhodium coordination, rather than covalent modication of residues other than cysteines. Purication by ultraltration, extensive dialysis or by passing through desalting columns could not remove the Rh complex, suggesting its strong binding to the protein. Literature has already reported the binding of up to 4 equivalents of [Cp*Rh(bipy)(H 2 O)]
2+ to the thermostable TADH, potentially to surface histidine and cysteine residues, without inuencing the catalytic activity of the enzyme. 17 Here, we observed a similar propensity of TbADH to unspecically bind rhodium complexes. Given that formation of a single TbADH species covalently bound to one rhodium complex could not be achieved, we proceeded with the evaluation of the mixture characterised above.
Formate dehydrogenase activity of articial metalloenzymes
The ability of the new articial metalloenzymes to reduce NADP + using formate as the hydride source was evaluated next, by following the increase of absorbance at 340 nm, due to the formation of NADPH (Table 1) . Interestingly, a lag phase could be observed for about 20-30 seconds at the beginning of the reactions, during which the enzyme activity was negligible, aer which time the reaction started (see ESI †). This might be due to the shielding effect of the protein matrix, slowing down the initial attachment of either formate or NADP + to the catalyst.
The turnover frequency (TOF) at 50 C was calculated from the reaction rate measured during linear absorbance increase. TOF was dened as the quantity of NADPH formed per unit of time (calculated using 3 340 ¼ 6220 M À1 cm À1 ), and divided by the quantity of the rhodium catalyst (determined by ICP-MS).
The activity of the brominated free catalysts [Cp*Rh(Br-L1) Cl]Cl and [Cp*Rh(Br-L2)Cl]Cl was similar to previous literature results (entries 1-2).
7,13 When covalently anchored to TbADH, the rhodium catalysts were less active than in their free form (entries 3-4), however their activities were comparable with previously published articial metalloenzymes for NAD + reduction.
28,30 Such a decrease in activity between free and protein-embedded catalysts has previously been observed for the NADH regeneration with biotinylated Cp*Ir complexes incorporated into streptavidin. 30 Some specicity for NADP + vs.
NAD + was observed with the bioconjugated Rh-bipyridine complex (Table 1 , entry 5), but not when the phenanthroline ligand was used. This result does not reect the NADP + -specicity of WT TbADH (specic activity is approx. 120 times higher with NADP + than with NAD + , see ESI †). This is likely due to the rhodium hydride in the articial metalloenzyme being more exposed than the zinc-bound alcoholate catalytic species in the wild-type enzyme, and possibly rearranging the cofactor binding.
Compatibility between bioconjugated Rh catalysts and TbADH
The mutual inactivation between the Rh-based catalysts and wild-type TbADH was assessed aer incubation at 50 C for 1 h and for 24 h (Fig. 4) 17 In our work, some residual Rh activity was still observed aer 1 h incubation, suggesting that the inactivating effect on the rhodium complex was less signicant with TbADH than with TADH. However, the activity of the complexes aer incubation with TbADH was far lower than in the absence of the enzyme.
When the bioconjugated catalysts were incubated with 1 equiv. TbADH, an increased stability was observed compared to the free complexes, with 42% and 33% residual activity observed aer 1 h incubation for [Cp*Rh(5M-C37L1)] 2+ and 15 mM) , sodium formate (500 mM), Rh catalyst (12.5 mM with articial metalloenzymes; 25 mM with free catalyst) in buffer (sodium phosphate, 100 mM, pH 7) at 50 C. The reduction rate was measured by monitoring the absorbance at 340 nm. 2+ . Rhodium catalysts (10 mM) were incubated with 1 equiv. WT TbADH (10 mM) in sodium phosphate buffer (100 mM, pH 7) at 50 C. Catalyst activity was determined by monitoring NADPH formation at 340 nm in the presence of formate (100 mM) at 50 C. In the absence of [Cp*Rh(5M-C37L2)] 2+ , respectively. This observation conrms that the protein scaffold acts as a shielding environment around the Rh catalysts, protecting these from deactivation by unspecic interactions with residues on the surface of the enzyme. Higher Rh/TbADH ratios resulted in increased relative activity of the complexes (see ESI †). The benecial effect of bioconjugation was even more prominent in the case of TbADH deactivation by the Rh catalysts. When exposed to 5 equivalents of Rh catalyst for 1 h, TbADH activity in the reduction direction remained relatively constant, irrespective of the type of catalyst used. However, when the incubation time was 24 h, the activity of TbADH decreased drastically when free Rh catalyst was present, but remained >80% in the presence of the articial metalloenzymes (Fig. 5) . Previous work by Steckhan and co-workers suggested no inhibition of TbADH aer incubation with 0.5 mM [Cp*Rh(bipy)(H 2 O)]Cl 2 , however their experiments were performed at 30 C and did not state the enzyme concentration.
8
On the other hand, Hollmann and co-workers have previously shown that inactivation of TADH by the same catalyst occurred upon incubation with more than 4 equiv. of Rh. Moreover, inactivation was pH-dependent, with 80% activity being retained aer 1 h incubation at pH 8 and room temperature, and only 25% of the TADH activity remaining aer incubation at pH 6 with 100-fold Rh molar excess. 17 In our hands, increased inactivation of TbADH by the Rh(III) complex can be observed at 50 C, but can be avoided by physically separating the complex from the enzyme surface, by encapsulation into the protein.
Cofactor recycling cascades
Encouraged by the benecial effect of bioconjugation on preventing mutual inactivation between TbADH and the Rh regeneration catalysts, we developed an ADH-hybrid catalyst cascade for the reduction of 4-phenyl-2-butanone. In this system, TbADH was used as the same protein scaffold for both ketone reduction and NADPH regeneration driven by formate (see Fig. 1 ).
The reduction of 4-phenyl-2-butanone by TbADH was tested at 50
C for 24 h, using 0.5% (mol) of either free or bioconjugated NADPH regeneration catalysts (see Fig. 1 ). Given the much lower turnover frequencies of Rh catalysts ($0.02 s À1 ) compared to TbADH ($2 s À1 for 2-butanone, data not shown), the amount of TbADH necessary to perform the transformation should be orders of magnitude lower than the amount of Rh. However, in line with stability studies, TbADH inactivation occurred at concentrations <1 mM, which resulted in the use of an optimised ratio of 25 mM Rh and 1.5 mM WT TbADH. The extent of inactivation was lower when bioconjugated catalysts were used (see ESI †). Although the initial activity of the free Rh catalysts for NADP + reduction was higher (see Table 1 ), the bioconjugated catalysts had better overall performance for the reduction of the ketone substrate, with 18-20% increase in conversion being observed (Table 2 ). This is likely to be due to the increased stability of both the ketone reduction, and the NADPH regeneration catalysts present in the same reaction vessel over 24 h. The enantioselectivity of the reaction was not affected by the presence of the catalyst, in either free or bioconjugated form (>99% ee (S) was obtained in all cases). Ketone reduction by the articial metalloenzymes was very slow, and could only be detected at rhodium concentrations much higher than those used in the regeneration experiments (TOF 0.1-0.2 h À1 ). This is in line with previous reports, where a very low turnover was observed with the [Cp*Rh(bipy)(H 2 O)] 2+ catalyst, compared to enzymatic ketone reduction, under aqueous conditions at neutral pH.
8,42
3 Experimental
Bioconjugation of metal complexes to TbADH
The gene encoding for wild-type TbADH bearing an N-terminal StrepTagII, cloned in the expression vector pET21a, was obtained from Biomatik (Ontario, Canada). Mutagenesis was performed using the QuikChange Lightning Site-Directed Fig. 5 Effect of the free and bioconjugated rhodium catalysts on 2-butanone reduction by WT TbADH. WT TbADH (1 mM) was incubated with the corresponding Rh catalyst (5 mM) in sodium phosphate buffer (100 mM, pH 7). In the absence of the Rh catalyst, the specific activity of WT TbADH (2-butanone reduction coupled to NADPH oxidation) after 1 h heating was 4.95 AE 0.37 U mg
À1
. a Catalysis conditions: 4-phenyl-2-butanone (5 mM), NADP + (0.5 mM), sodium formate (500 mM), Rh catalyst (25 mM), WT TbADH (1.5 mM) in buffer (sodium phosphate, 100 mM, pH 7) at 50 C. Conversion and enantioselectivities were determined aer 24 h by chiral HPLC, using a CHIRALCEL OD column. Conversion are presented as averages of triplicate runs, and standard deviations were <1%. Enantioselectivities were >99% ee in favour of the (S)-enantiomer, in all cases.
Mutagenesis Kit (Agilent Technologies), following manufacturer's instructions. Recombinant overexpression was carried out in E. coli BL21(DE3). Wild-type TbADH and mutants H59A-D150A-C203S-C283A-C295A (5M) and C203S-C283A-C295A (3M) were routinely characterized by SDS-PAGE, enzymatic activity, protein concentration, ICP-MS to determine metal content and Ellman assay to determine availability of thiol groups. The wildtype TbADH sequence, primers used for mutagenesis and details of protein expression, purication and characterisation can be found in the ESI. † Ligands Br-L1 and Br-L2, and metal complexes [Cp*Rh(Br-L1)Cl]Cl and [Cp*Rh(Br-L1)Cl]Cl were synthesized according to the literature.
Covalent conjugation of complexes [Cp*Rh(Br-L1)Cl]Cl and [Cp*Rh(Br-L1)Cl]Cl to TbADH 5M was performed in 100 mM Tris-HCl pH 7, by incubating 4-fold molar excess of the brominated Rh catalysts with TbADH 5M, for 1 h at room temperature. Unbound catalyst was removed by desalting through a PD-10 column (GE Healthcare), followed by concentration by ultraltration with Vivaspin 6 (10 kDa MWCO, Sartorius). The owthrough was routinely tested for the absence of catalytic activity and Rh content, thus supporting the absence of free catalyst in the articial metalloenzyme preparations. UVvisible absorbance spectra were acquired in 100 mM sodium phosphate pH 7 with a Cary 8454 spectophotometer (Agilent Technologies). Rh content was determined by inductively coupled plasma mass spectrometry (ICP-MS) with a Thermo Fisher iCAP-Q instrument, aer digestion of the protein in nitric acid (trace metal grade, Fisher Scientic) as previously described. 43 Mass spectrometry analysis was performed by electrospray ionisation time-of-ight (ESI-TOF) in a Bruker Impact II spectrometer. Before analysis, the protein samples were desalted in pure water, concentrated up to $5 mg mL À1 and then mixed with 1 volume of 0.1% formic acid in acetonitrile.
Formate-driven NAD(P)
+ reduction assays
The reduction rate was measured by monitoring the absorbance at 340 nm (3 ¼ 6220 M À1 cm À1 ) with a Shimadzu UV-2600 spectrophotometer, equipped with CPS-100 temperature controller. Reactions were performed as previously described, 7 in 100 mM sodium phosphate, 500 mM sodium formate pH 7 at 50 C. NAD(P) + concentration was 0.15 mM. Control experiments were carried out in the absence of any catalyst or in the absence of formate.
Stability assays
Metal concentration was determined by weight (free catalysts) or by ICP-MS (articial metalloenzyme). Stability tests were adapted from previously reported mutual inactivation experiments with [Cp*Rh(Bipy)H 2 O] 2+ and TADH. 17 To test the inactivation of the Rh catalyst by TbADH, 10 mM Rh catalyst (nonbrominated complex, or corresponding articial metalloenzyme) was incubated with 10 mM TbADH in 100 mM sodium phosphate pH 7 at 50 C. Samples were taken aer 1 h or 24 h and the residual activity was assayed spectrophotometrically aer the addition of sodium formate (100 mM nal concentration) and NADP + (0.15 mM nal concentration).
To test the inactivation of TbADH by the Rh catalyst, 1 mM TbADH was incubated with 5 mM Rh catalyst (non-brominated catalyst, or corresponding articial metalloenzyme) in 100 mM sodium phosphate pH 7 at 50 C. Samples were taken aer 1 h or 24 h and the residual activity was assayed spectrophotometrically aer the addition of 2-butanone (50 mM nal concentration) and NADPH (0.2 mM nal concentration).
NADPH recycling assays
The assay was performed by adapting previous literature protocols. 8 The reaction mixture (250 mL) contained 4-phenyl-2-butanone (5 mM), TbADH (1.5 mM), NADP + (0.5 mM), Rh catalyst (non-brominated catalyst, or corresponding articial metalloenzyme, 25 mM) and sodium formate (500 mM), in 100 mM sodium phosphate pH 7. The mixture was incubated for 24 h at 50 C, then cooled to room temperature, extracted with 1 volume of hexane, dried over Na 2 SO 4 and analysed by chiral HPLC. The analysis was performed with an Agilent 1220 Innity equipped with a CHIRALCEL® OD column (4.6 mm Â 250 mm; particle size 10 mm). The separation was isocratic at 1 mL min À1 , using an isopropanol/hexane mixture 6/94 (v/v). The detection wavelength was 215 nm. Quantication was achieved by comparing peak area against standard solutions. Omitting any of the component from the reaction mixture resulted in no conversion.
Conclusions
Alcohol dehydrogenase was for the rst time used as a protein host for the design and creation of articial metalloenzymes. Cp*Rh(III) complexes of bipyridine and phenanthroline bearing an electrophilic moiety were covalently anchored to thermostable TbADH devoid of active site zinc and containing a single cysteine in the protein sequence. The resulting conjugated complexes were shown to catalyse the reduction of NADP + at 50 C. The mutual inactivation between wild-type TbADH and the ADH-based articial metalloenzymes was evaluated and showed an increased stability of both the rhodium catalysts and the wild-type TbADH, when bioconjugated species were used instead of free complexes. The ADH-based articial metalloenzymes were successfully combined in cofactor recycling cascades with wild-type TbADH, and afforded higher conversions compared to the free catalysts for the enantioselective reduction of 4-phenyl-2-butanone. The activity of these articial metalloenzymes remains 2 orders of magnitude lower than the activity of recently discovered NADP + -dependent native formate dehydrogenase systems (0.02 s À1 vs. up to 4.8 s À1 ). 44 However, their compatibility with high temperatures and neutral pH makes them interesting candidates for further development of regeneration methods with bioconjugated transition metal complexes. Further research is in progress to optimise the conjugation site and to improve the binding specicity of rhodium complexes to TbADH. Additional metals such as Ru and Ir, as well as different ligand architectures will also be considered, given their reported ability to reduce nicotinamide cofactors.
Conflicts of interest
There are no conicts to declare.
